These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2889160)

  • 1. Behavioural and ECoG spectrum power effects after intraventricular injection of drugs altering dopaminergic transmission in rats.
    Bagetta G; Corasaniti MT; Strongoli MC; Sakurada S; Nisticò G
    Neuropharmacology; 1987 Aug; 26(8):1047-52. PubMed ID: 2889160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats.
    Bagetta G; De Sarro G; Priolo E; Nisticò G
    Br J Pharmacol; 1988 Nov; 95(3):860-6. PubMed ID: 2974741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrocortical spectrum power effects of different classes of neuroleptics in rats.
    Bagetta G; Corasaniti MT; Strongoli MC; Sakurada S; Nisticò G
    J Psychiatr Res; 1987; 21(1):93-9. PubMed ID: 2882023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms.
    De Sarro GB; Ascioti C; Froio F; Libri V; Nisticò G
    Br J Pharmacol; 1987 Apr; 90(4):675-85. PubMed ID: 2884006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different profile of electrocortical power spectrum changes after micro-infusion into the locus coeruleus of selective agonists at various opioid receptor subtypes in rats.
    Bagetta G; De Sarro GB; Sakurada S; Rispoli V; Nisticò G
    Br J Pharmacol; 1990 Nov; 101(3):655-61. PubMed ID: 1963804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated treatment with (-)-sulpiride plus a low dose of SCH 23390 displays wider neuroleptic activity without inducing dopaminergic supersensitivity.
    Dall'Olio R; Gandolfi O; Roncada P; Vaccheri A; Montanaro N
    Psychopharmacology (Berl); 1990; 100(4):560-2. PubMed ID: 1969667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390.
    Molloy AG; Waddington JL
    Psychopharmacology (Berl); 1984; 82(4):409-10. PubMed ID: 6427836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H; Gerlach J; Peacock L
    Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic blockade of some dopamine-mediated behaviours by (-)-sulpiride and SCH 23390 in the rat.
    Dall'Olio R; Roncada P; Vaccheri A; Gandolfi O; Montanaro N
    Psychopharmacology (Berl); 1989; 98(3):342-6. PubMed ID: 2568655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of dopamine D-1 and D-2 receptor agonists on EEG activity and behaviour in the rabbit.
    Ongini E; Caporali MG
    Neuropharmacology; 1987 Apr; 26(4):355-60. PubMed ID: 2953987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in behavioural responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats.
    Dall'Olio R; Gandolfi O; Vaccheri A; Roncada P; Montanaro N
    Psychopharmacology (Berl); 1988; 95(3):381-5. PubMed ID: 2901128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
    Zarkovsky AM; Cereska KS
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on electroencephalogram (EEG) in rats suggest that moderate doses of cocaine or d-amphetamine activate D1 rather than D2 receptors.
    Ferger B; Kropf W; Kuschinsky K
    Psychopharmacology (Berl); 1994 Mar; 114(2):297-308. PubMed ID: 7838923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopamine D1 and D2 receptor agonists and antagonists on bombesin-induced behaviors.
    Merali Z; Piggins H
    Eur J Pharmacol; 1990 Dec; 191(3):281-93. PubMed ID: 2086245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of dopamine D-1 receptors by SKF 38393 induces EEG desynchronization and behavioral arousal.
    Ongini E; Caporali MG; Massotti M
    Life Sci; 1985 Dec; 37(24):2327-33. PubMed ID: 3877855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants.
    Serra G; Collu M; D'Aquila PS; De Montis GM; Gessa GL
    Brain Res; 1990 Sep; 527(2):234-43. PubMed ID: 1979237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.
    Glenthøj B
    Psychopharmacology (Berl); 1993; 113(2):157-66. PubMed ID: 7855176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.